Literature DB >> 7684411

The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes.

P Engel1, Y Nojima, D Rothstein, L J Zhou, G L Wilson, J H Kehrl, T F Tedder.   

Abstract

CD22 is a B lineage-restricted member of the Ig superfamily that serves as an adhesion receptor expressed by mature B lymphocytes. In this study, the ability of different cell types to attach to COS cells transiently transfected with a full-length CD22 cDNA (COS-CD22) was examined to determine the cellular distribution of the ligand for CD22. T and B lymphocytes, monocytes, erythrocytes, and neutrophils formed specific rosettes with COS-CD22 cells at 4 degrees C. A panel of 33 new mAb directed against CD22 were developed to examine the regions of CD22 that mediate adhesion. Four of these mAb, HB22-7, -22, -23, and -33 (at 1 to 5 micrograms/ml) specifically blocked adhesion (75 to 95%) of all cell types to COS-CD22 cells. Each of these mAb cross-blocked each other's binding, suggesting that ligand binding occurs through a single region of CD22. These mAb also identify a region of CD22 distinct from those defined by previously described CD22 mAb. CD22-mediated adhesion of cell lines to COS-CD22 cells was independent of CD45RO and CDw75 expression, and it was not inhibited by mAb against known integrins. Although alpha-2,6-linked sialic acid expressed on the surface of COS cells did not serve as a ligand for CD22, the CD22 ligand may contain a critical sialic acid determinant, as neuraminidase treatment of all target cells eliminated CD22-mediated adhesion. CD22-mediated adhesion was Ca2+/Mg2+ independent, again suggesting that integrins were not involved. An inhibitory substance for CD22-mediated adhesion was found to be present in FCS and some ascites fluid. Analysis of CD22 mRNA and protein revealed that although multiple mRNA splice variants of CD22 mRNA can be detected, only a single protein isoform was detected on the cell surface. Therefore, although the identity of the CD22 ligands remains incompletely characterized, it is possible that a single major ligand is expressed by RBC and leukocytes, which binds to a single region of CD22.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684411

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

Review 1.  Siglecs in the immune system.

Authors:  P R Crocker; A Varki
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

2.  Dendritic cell-dependent inhibition of B cell proliferation requires CD22.

Authors:  Lorna Santos; Kevin E Draves; Mark Boton; Prabhjit K Grewal; Jamey D Marth; Edward A Clark
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

3.  A reevaluation of CD22 expression in human lung cancer.

Authors:  Laurentiu M Pop; Stephen Barman; Chunli Shao; Jonathan C Poe; Guglielmo M Venturi; John M Shelton; Iliodora V Pop; David E Gerber; Luc Girard; Xiao-yun Liu; Carmen Behrens; Jaime Rodriguez-Canales; Hui Liu; Ignacio I Wistuba; James A Richardson; John D Minna; Thomas F Tedder; Ellen S Vitetta
Journal:  Cancer Res       Date:  2014-01-01       Impact factor: 12.701

Review 4.  Investigational immunotherapeutics for B-cell malignancies.

Authors:  Alfonso Quintás-Cardama; William Wierda; Susan O'Brien
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544

5.  In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.

Authors:  T N C Ramya; Eranthie Weerapana; Lujian Liao; Ying Zeng; Hiroaki Tateno; Liang Liao; John R Yates; Benjamin F Cravatt; James C Paulson
Journal:  Mol Cell Proteomics       Date:  2010-02-19       Impact factor: 5.911

6.  A novel subset of murine B cells that expresses unmasked forms of CD22 is enriched in the bone marrow: implications for B-cell homing to the bone marrow.

Authors:  H Floyd; L Nitschke; P R Crocker
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

7.  Overexpressed Ly-6A.2 mediates cell-cell adhesion by binding a ligand expressed on lymphoid cells.

Authors:  A Bamezai; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

8.  Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact.

Authors:  Brian E Collins; Ola Blixt; Alexis R DeSieno; Nicolai Bovin; Jamey D Marth; James C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

9.  Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.

Authors:  Noriko Satake; Connie Duong; Sakiko Yoshida; Michael Oestergaard; Cathy Chen; Rachael Peralta; Shuling Guo; Punit P Seth; Yueju Li; Laurel Beckett; Jong Chung; Jan Nolta; Nitin Nitin; Joseph M Tuscano
Journal:  Mol Med       Date:  2016-07-22       Impact factor: 6.354

10.  Modifications of cell surface sialic acids modulate cell adhesion mediated by sialoadhesin and CD22.

Authors:  S Kelm; R Schauer; J C Manuguerra; H J Gross; P R Crocker
Journal:  Glycoconj J       Date:  1994-12       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.